1184 Pulmonary Vasodilator Action Of Tolazoline In The Newborn View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1978-04

AUTHORS

Boyd W Goetzman, Jay M Milstein, Richard P Wennberg

ABSTRACT

Tolazoline has been reported to reduce the elevated pulmonary vascular resistance found in some clinical conditions, including the syndrome of persistence of the fetal circulation in the newborn. Tolazoline, an ≥-adrenergic blocking agent, also has direct actions on cardiac and smooth muscle which are described as “histamine-like.” We evaluated the pulmonary vasodilator effect of tolazoline in newborn lambs before and after the administration of the specific histamine H1- and H2-receptor antagonists, diphenhydramine and metiamide, respectively. Lambs, 0-3 days old, were anesthetized and instrumented for measurement of pulmonary artery pressure, left atrial pressure and pulmonary blood flow. Pulmonary vascular resistance, PVR, was then calculated. Pharmacologic agents were administered in bolus form via the inferior vena cava in the following doses: tolazoline, 1 mg/kg; diphenhydramine, 5 mg/kg; and metiamide, 5 mg/kg. The mean change in pulmonary vascular resistance, %ΔPVR, produced by tolazoline after histamine receptor blockade is given below.It is concluded that the pulmonary vasodilator action of tolazoline is entirely mediated by histamine H1- and H2 receptors. More... »

PAGES

561-561

Identifiers

URI

http://scigraph.springernature.com/pub.10.1203/00006450-197804001-01190

DOI

http://dx.doi.org/10.1203/00006450-197804001-01190

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046714831


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of California, Davis - Sacramento Medical Center, Sacramento, California", 
          "id": "http://www.grid.ac/institutes/grid.27860.3b", 
          "name": [
            "University of California, Davis - Sacramento Medical Center, Sacramento, California"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goetzman", 
        "givenName": "Boyd W", 
        "id": "sg:person.01000233111.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000233111.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, Davis - Sacramento Medical Center, Sacramento, California", 
          "id": "http://www.grid.ac/institutes/grid.27860.3b", 
          "name": [
            "University of California, Davis - Sacramento Medical Center, Sacramento, California"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Milstein", 
        "givenName": "Jay M", 
        "id": "sg:person.01203256140.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203256140.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, Davis - Sacramento Medical Center, Sacramento, California", 
          "id": "http://www.grid.ac/institutes/grid.27860.3b", 
          "name": [
            "University of California, Davis - Sacramento Medical Center, Sacramento, California"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wennberg", 
        "givenName": "Richard P", 
        "id": "sg:person.070063300.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.070063300.96"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1978-04", 
    "datePublishedReg": "1978-04-01", 
    "description": "Tolazoline has been reported to reduce the elevated pulmonary vascular resistance found in some clinical conditions, including the syndrome of persistence of the fetal circulation in the newborn. Tolazoline, an \u2265-adrenergic blocking agent, also has direct actions on cardiac and smooth muscle which are described as \u201chistamine-like.\u201d We evaluated the pulmonary vasodilator effect of tolazoline in newborn lambs before and after the administration of the specific histamine H1- and H2-receptor antagonists, diphenhydramine and metiamide, respectively. Lambs, 0-3 days old, were anesthetized and instrumented for measurement of pulmonary artery pressure, left atrial pressure and pulmonary blood flow. Pulmonary vascular resistance, PVR, was then calculated. Pharmacologic agents were administered in bolus form via the inferior vena cava in the following doses: tolazoline, 1 mg/kg; diphenhydramine, 5 mg/kg; and metiamide, 5 mg/kg. The mean change in pulmonary vascular resistance, %\u0394PVR, produced by tolazoline after histamine receptor blockade is given below.It is concluded that the pulmonary vasodilator action of tolazoline is entirely mediated by histamine H1- and H2 receptors.", 
    "genre": "article", 
    "id": "sg:pub.10.1203/00006450-197804001-01190", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1007352", 
        "issn": [
          "0031-3998", 
          "1530-0447"
        ], 
        "name": "Pediatric Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "pulmonary vascular resistance", 
      "vascular resistance", 
      "histamine H1", 
      "elevated pulmonary vascular resistance", 
      "pulmonary vasodilator effect", 
      "specific histamine H1", 
      "histamine receptor blockade", 
      "pulmonary vasodilator action", 
      "pulmonary artery pressure", 
      "pulmonary blood flow", 
      "H2-receptor antagonists", 
      "inferior vena cava", 
      "adrenergic blocking agent", 
      "artery pressure", 
      "vasodilator effect", 
      "vasodilator action", 
      "atrial pressure", 
      "receptor blockade", 
      "fetal circulation", 
      "vena cava", 
      "pharmacologic agents", 
      "H2 receptors", 
      "blocking agent", 
      "mean change", 
      "clinical conditions", 
      "smooth muscle", 
      "blood flow", 
      "bolus form", 
      "tolazoline", 
      "newborn lambs", 
      "direct action", 
      "metiamide", 
      "newborns", 
      "diphenhydramine", 
      "pulmonary", 
      "lambs", 
      "cava", 
      "blockade", 
      "syndrome", 
      "antagonist", 
      "agents", 
      "\u0394PVR", 
      "PVR", 
      "administration", 
      "doses", 
      "receptors", 
      "action", 
      "muscle", 
      "resistance", 
      "days", 
      "pressure", 
      "circulation", 
      "H1", 
      "persistence", 
      "effect", 
      "changes", 
      "form", 
      "conditions", 
      "measurements", 
      "flow"
    ], 
    "name": "1184 PULMONARY VASODILATOR ACTION OF TOLAZOLINE IN THE NEWBORN", 
    "pagination": "561-561", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046714831"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1203/00006450-197804001-01190"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1203/00006450-197804001-01190", 
      "https://app.dimensions.ai/details/publication/pub.1046714831"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_128.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1203/00006450-197804001-01190"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1203/00006450-197804001-01190'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1203/00006450-197804001-01190'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1203/00006450-197804001-01190'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1203/00006450-197804001-01190'


 

This table displays all metadata directly associated to this object as RDF triples.

136 TRIPLES      21 PREDICATES      87 URIs      78 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1203/00006450-197804001-01190 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 anzsrc-for:1115
4 schema:author N8ea55a171f964b57bc2eab64e58cbbb0
5 schema:datePublished 1978-04
6 schema:datePublishedReg 1978-04-01
7 schema:description Tolazoline has been reported to reduce the elevated pulmonary vascular resistance found in some clinical conditions, including the syndrome of persistence of the fetal circulation in the newborn. Tolazoline, an ≥-adrenergic blocking agent, also has direct actions on cardiac and smooth muscle which are described as “histamine-like.” We evaluated the pulmonary vasodilator effect of tolazoline in newborn lambs before and after the administration of the specific histamine H1- and H2-receptor antagonists, diphenhydramine and metiamide, respectively. Lambs, 0-3 days old, were anesthetized and instrumented for measurement of pulmonary artery pressure, left atrial pressure and pulmonary blood flow. Pulmonary vascular resistance, PVR, was then calculated. Pharmacologic agents were administered in bolus form via the inferior vena cava in the following doses: tolazoline, 1 mg/kg; diphenhydramine, 5 mg/kg; and metiamide, 5 mg/kg. The mean change in pulmonary vascular resistance, %ΔPVR, produced by tolazoline after histamine receptor blockade is given below.It is concluded that the pulmonary vasodilator action of tolazoline is entirely mediated by histamine H1- and H2 receptors.
8 schema:genre article
9 schema:inLanguage en
10 schema:isAccessibleForFree true
11 schema:isPartOf N77c48c489dbb4cdcaba162043c038398
12 N800dfcc1f9d7417c994119eaaf13df5e
13 sg:journal.1007352
14 schema:keywords H1
15 H2 receptors
16 H2-receptor antagonists
17 PVR
18 action
19 administration
20 adrenergic blocking agent
21 agents
22 antagonist
23 artery pressure
24 atrial pressure
25 blockade
26 blocking agent
27 blood flow
28 bolus form
29 cava
30 changes
31 circulation
32 clinical conditions
33 conditions
34 days
35 diphenhydramine
36 direct action
37 doses
38 effect
39 elevated pulmonary vascular resistance
40 fetal circulation
41 flow
42 form
43 histamine H1
44 histamine receptor blockade
45 inferior vena cava
46 lambs
47 mean change
48 measurements
49 metiamide
50 muscle
51 newborn lambs
52 newborns
53 persistence
54 pharmacologic agents
55 pressure
56 pulmonary
57 pulmonary artery pressure
58 pulmonary blood flow
59 pulmonary vascular resistance
60 pulmonary vasodilator action
61 pulmonary vasodilator effect
62 receptor blockade
63 receptors
64 resistance
65 smooth muscle
66 specific histamine H1
67 syndrome
68 tolazoline
69 vascular resistance
70 vasodilator action
71 vasodilator effect
72 vena cava
73 ΔPVR
74 schema:name 1184 PULMONARY VASODILATOR ACTION OF TOLAZOLINE IN THE NEWBORN
75 schema:pagination 561-561
76 schema:productId N2ea217d1f46f4bcc987bb494a945cfc7
77 Ne0341d710c4844b48a4846fc19c57e8f
78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046714831
79 https://doi.org/10.1203/00006450-197804001-01190
80 schema:sdDatePublished 2022-05-20T07:17
81 schema:sdLicense https://scigraph.springernature.com/explorer/license/
82 schema:sdPublisher N1156dabf303a4aaebfaa7354115013f6
83 schema:url https://doi.org/10.1203/00006450-197804001-01190
84 sgo:license sg:explorer/license/
85 sgo:sdDataset articles
86 rdf:type schema:ScholarlyArticle
87 N1156dabf303a4aaebfaa7354115013f6 schema:name Springer Nature - SN SciGraph project
88 rdf:type schema:Organization
89 N2ea217d1f46f4bcc987bb494a945cfc7 schema:name dimensions_id
90 schema:value pub.1046714831
91 rdf:type schema:PropertyValue
92 N4b8e4639e0a44b33a625ccc73a3fa6fc rdf:first sg:person.070063300.96
93 rdf:rest rdf:nil
94 N77c48c489dbb4cdcaba162043c038398 schema:issueNumber Suppl 4
95 rdf:type schema:PublicationIssue
96 N800dfcc1f9d7417c994119eaaf13df5e schema:volumeNumber 12
97 rdf:type schema:PublicationVolume
98 N8ea55a171f964b57bc2eab64e58cbbb0 rdf:first sg:person.01000233111.32
99 rdf:rest Nad58d1df4e494511ab1e4c2d14cc3f6e
100 Nad58d1df4e494511ab1e4c2d14cc3f6e rdf:first sg:person.01203256140.23
101 rdf:rest N4b8e4639e0a44b33a625ccc73a3fa6fc
102 Ne0341d710c4844b48a4846fc19c57e8f schema:name doi
103 schema:value 10.1203/00006450-197804001-01190
104 rdf:type schema:PropertyValue
105 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
106 schema:name Medical and Health Sciences
107 rdf:type schema:DefinedTerm
108 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
109 schema:name Cardiorespiratory Medicine and Haematology
110 rdf:type schema:DefinedTerm
111 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
112 schema:name Pharmacology and Pharmaceutical Sciences
113 rdf:type schema:DefinedTerm
114 sg:journal.1007352 schema:issn 0031-3998
115 1530-0447
116 schema:name Pediatric Research
117 schema:publisher Springer Nature
118 rdf:type schema:Periodical
119 sg:person.01000233111.32 schema:affiliation grid-institutes:grid.27860.3b
120 schema:familyName Goetzman
121 schema:givenName Boyd W
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000233111.32
123 rdf:type schema:Person
124 sg:person.01203256140.23 schema:affiliation grid-institutes:grid.27860.3b
125 schema:familyName Milstein
126 schema:givenName Jay M
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203256140.23
128 rdf:type schema:Person
129 sg:person.070063300.96 schema:affiliation grid-institutes:grid.27860.3b
130 schema:familyName Wennberg
131 schema:givenName Richard P
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.070063300.96
133 rdf:type schema:Person
134 grid-institutes:grid.27860.3b schema:alternateName University of California, Davis - Sacramento Medical Center, Sacramento, California
135 schema:name University of California, Davis - Sacramento Medical Center, Sacramento, California
136 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...